CoChat

Dipeptidyl peptidase‐4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells

Open access
Huang, Chun‐Yao, Shih, Chun‐Ming, Tsao, Nai‐Wen, Lin, Yi‐Wen, Huang, Po‐Hsun, Wu, Shinn‐Chih, Lee, Ai‐Wei, Kao, Yung‐Ta, Chang, Nen‐Chung, Nakagami, Hironori, Morishita, Ryuichi, Ou, Keng‐Liang, Hou, Wen‐Chi, Lin, Cheng‐Yen, Shyu, Kuo‐Gi, Lin, Feng‐Yen · 2012 · British Journal of Pharmacology
Cited by 81

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND PURPOSE Current methods used to treat critical limb ischaemia (CLI) are hampered by a lack of effective strategies, therefore, therapeutic vasculogenesis may open up a new field for the treatment of CLI. In this study we investigated the ability of the DPP‐4 inhibitor, sitagliptin, originally used as a hypoglycaemic agent, to induce vasculogenesis in vivo. EXPERIMENTAL APPROACH Sitagliptin were administered daily to C57CL/B6 mice and eGFP transgenic mouse bone marrow‐transplanted ICR mice that had undergone hindlimb ischaemic surgery. Laser Doppler imaging and flow cytometry were used to evaluate the degree of neovasculogenesis and circulating levels of endothelial progenitor cells (EPCs) respectively. Cell surface markers of EPCs and endothelial NOS (eNOS) in vessels were studied. KEY RESULTS Sitagliptin elevated plasma glucagon‐like peptide‐1 (GLP‐1) levels in mice subjected to ischaemia, decreased plasma dipeptidyl peptidase‐4 (DPP‐4) concentration, and augmented ischaemia‐induced increases in stromal cell‐derived factor‐1 (SDF‐1) in a dose‐dependent manner. Blood flow in the ischaemic limb was significantly improved in mice treated with sitagliptin. Circulating levels of EPCs were also increased after sitagliptin treatment. Sitagliptin also enhanced the expression of CD 34 and eNOS in ischaemic muscle. In addition, sitagliptin promoted EPC mobilization and homing to ischaemic tissue in eGFP transgenic mouse bone marrow‐transplanted ICR mice. CONCLUSION AND IMPLICATIONS Circulating EPC levels and neovasculogenesis were augmented by the DPP‐4 inhibitor, sitagliptin and this effect was dependent on an eNOS‐related pathway in a mouse model of hindlimb ischaemia. The results indicate that oral administration of sitagliptin has therapeutic potential as an inducer of vasculogenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.2012.02102.x

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 81

Metadata

Authors
Huang, C., Shih, C., Tsao, N., Lin, Y., Huang, P., Wu, S., Lee, A., Kao, Y., Chang, N., Nakagami, H., Morishita, R., Ou, K., Hou, W., Lin, C., Shyu, K., & Lin, F.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2012-11-06
Volume
167
Issue
7
Pages
1506-1519
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1517096356
Cited by
81
References
10
FWCI
3.37
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dipeptidyl peptidase‐4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells. https://app.cochat.ai/papers/10.1111/j.1476-5381.2012.02102.x
The paper
Huang, C., Shih, C., Tsao, N., Lin, Y., Huang, P., Wu, S., Lee, A., Kao, Y., Chang, N., Nakagami, H., Morishita, R., Ou, K., Hou, W., Lin, C., Shyu, K., & Lin, F. (2012). Dipeptidyl peptidase‐4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2012.02102.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.